Serum semaphorin 4C as a diagnostic biomarker in breast cancer: A multicenter retrospective study.

ABSTRACT:

Background

To date, there is no approved blood-based biomarker for breast cancer detection. Herein, we aimed to assess semaphorin 4C (SEMA4C), a pivotal protein involved in breast cancer progression, as a serum diagnostic biomarker.

Methods

We included 6,213 consecutive inpatients from Tongji Hospital, Qilu Hospital, and Hubei Cancer Hospital. Training cohort and two validation cohorts were introduced for diagnostic exploration and validation. A pan-cancer cohort was used to independently explore the diagnostic potential of SEMA4C among solid tumors. Breast cancer patients who underwent mass excision prior to modified radical mastectomy were also analyzed. We hypothesized that increased pre-treatment serum SEMA4C levels, measured using optimized in-house enzyme-linked immuno

SUBMITTER: Wang Y 

PROVIDER: S-EPMC8696225 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature